Skip to main content

Table 4 Statistical analysis of three groups of POLAR validation set for 0–10 years of follow-up

From: Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer

 

All POLAR patients

Chemotherapy-treated

Chemotherapy-naive

0–10 Years

No. of patients (relapses)

n = 422 (247)

n = 170 (99)

n = 252 (148)

Univariate

CTS

LRχ2

11.23

7.75

6.1

P

< 0.001

0.005

0.014

C-index (SE)

0.594 (0.028)

0.623 (0.044)

0.590 (0.036)

10-Year signature

LRχ2

12.44

7.73

5.39

P

< 0.004

0.005

0.020

C-index (SE)

0.593 (0.028)

0.619 (0.044)

0.578 (0.037)

Multivariable comparisons

CTS + 10-year signature vs CTS

ΔLRχ2

7.74

6.71

2.47

P

0.005

0.001

0.116

CTS + 10-year signature

C-index (SE)

0.617 (0.028)

0.669 (0.042)

0.598 (0.036)

  1. Abbreviations: POLAR Molecular Predictors Of early versus LAte Recurrence in ER-positive breast cancer, CTS Clinical Treatment Score, LR Likelihood ratio, SE standard error
  2. Both univariate and multivariable analyses are presented for years 0–10, years 0–5, and years 5–10 separately. Likelihood ratio test based on Cox proportional hazards models for univariate and multivariable analyses. Differences in likelihood ratio values (ΔLRχ2) were used. CTS was used as a covariate in the multivariable regressions
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us